Medindia LOGIN REGISTER
Medindia

How Do Blood Cancer Patients Respond to COVID-19 Vaccines?

by Dr. Jayashree Gopinath on Jul 12 2022 10:48 PM
Listen to this article
0:00/0:00

How Do Blood Cancer Patients Respond to COVID-19 Vaccines?
Less than half of cancer patients had detectable antibodies after the initial COVID-19 vaccination, but 56% of nonresponders produced antibodies after receiving a booster dose. This finding is according to a recent study published in the CANCER, a peer-reviewed journal of the American Cancer Society.
People with blood cancers including leukemia, lymphoma, and multiple myeloma have an impaired immune system due to their disease and its treatment, putting them at risk of severe COVID-19 infection and experiencing a reduced response to COVID-19 vaccination.

For the study, researchers retrospectively analyzed antibody responses to initial and booster COVID-19 vaccination in 378 patients with blood cancer.

Anti-SARS-CoV-2 antibodies were detected in the blood of 181 patients (48%) after initial vaccination with one of three U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccines, and patients with active cancer or those recently treated with an immune cell–depleting therapy were least likely to produce these antibodies.

COVID-19 Vaccine Efficacy and Blood Cancer

Among patients who did not mount an antibody response following initial vaccination, responses were observed after a booster dose in 48 of 85 (56%) patients who were assessed.

By the end of February 2022, 33 patients (8.8%) developed a COVID-19 infection, with three COVID-19-related deaths (0.8%).

Although there was no significant link between post-vaccination antibody response and incidence of COVID-19 infection, no patient with antibody responses died from COVID-19.

Also, no patient who received Tixagevimab plus Cilgavimab was diagnosed with a COVID-19 infection. Tixagevimab and Cilgavimab are antibody therapies that bind to non-overlapping portions of the SARS-CoV-2 spike protein, preventing the virus from binding to and infecting cells.

Advertisement
The FDA authorized the combination therapy for emergency use during the COVID-19 pandemic as a way to help prevent COVID-19 infection in certain individuals. These findings build on the wealth of literature showing that patients with hematologic malignancies have an impaired response to COVID vaccination.

This study also suggests to us the importance of checking antibody levels in these patients and arranging prophylactic antibody therapy. It also encourages providing booster vaccines for patients and prioritizing prophylactic antibody therapy when indicated.

Advertisement
This is real-world evidence that these actions can save lives.



Source-Medindia


Recommended Readings
Advertisement